8-K

QHSLab, Inc. (USAQ)

8-K 2024-04-26 For: 2024-04-26
View Original
Added on April 06, 2026

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): April 26, 2024

QHSLab,Inc.

(Exact Name of Registrant as Specified in its Charter)

0-19041

(Commission File No.)

Nevada 30-1104301
(State<br><br> <br>of<br> Incorporation) (I.R.S.<br> Employer<br><br> <br>Identification<br> No.)
901<br> Northpoint Parkway Suite 302 West Palm Beach<br><br> <br>FL<br> 33407 33407
(Address<br> of Principal Executive Offices) (ZIP<br> Code)

Registrant’s telephone number, including area code: (929) 379-6503

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securitiesregistered pursuant to Section 12(g) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par value USAQ N/A

Item7.01 Regulation FD Disclosure.

On April 26, 2024, QHSLab, Inc. (the “Company”), announced preliminary unaudited first quarter results. The full text of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

We use, and will continue to use, our website (https://usaqcorp.com), press releases, and various social media channels, including our Twitter account (https://twitter.com/qhslabinc), LinkedIn account (https://www.linkedin.com/company/65407282/), Facebook account (https://www.facebook.com/QHSLabs) and Instagram account (https://www.instagram.com/qhslabs/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information we post on our website, disseminate in press releases and on social media could be deemed to be material information, and we encourage investors, the media and others interested in the Company to review the business and financial information that we post on our website, disseminate in press releases and on the social media channels identified above, as such information could be deemed to be material information.

Item9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

Exhibit<br><br> <br>No. Description
99.1 Press Release dated April 26, 2024 – QHSLab, Inc. Announces Preliminary Unaudited First Quarter Revenue Results
104 Cover<br> Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date:<br> April 26, 2024
QHSLab,<br> Inc.
/s/ Troy Grogan
Name: Troy<br> Grogan
Title: CEO<br> and Chairman

Exhibit99.1

QHSLab,Inc. Announces Preliminary Unaudited First Quarter Revenue Results


WESTPALM BEACH, FL, April 26, 2024 (GLOBE NEWSWIRE) — QHSLab, Inc. (“the Company”) (OTCQB: USAQ), a leader in digital health and point-of-care technologies designed to empower clinicians with proactive, value-based healthcare solutions, today announced its preliminary unaudited revenue for the first quarter ended March 31, 2024.

FinancialHighlights:

First Quarter Revenues were $488,587, a 38% increase over the $352,799 reported in the first quarter of 2023.
First Quarter Gross Profit was $286,157, with a gross profit margin of 59%, compared to $187,342 or a gross profit margin of 53% during<br> the same period last year. This marks a 53% increase in gross profit year-over-year.

ExecutiveCommentary: Troy Grogan, President and CEO of QHSLab, Inc., stated, “Our strong preliminary results for the first quarter reflect a pivotal inflection point in our business. We are witnessing the benefits of integrating our core products—QHSLab software, Integrated Service Program (ISP), and AllergiEnd®. This synergy is not only solidifying our market position but is also resonating well with our physician clients and their patients. The growing demand for integrated allergy care and digital health assessments is expected to continue driving our growth.”

AdditionalInformation: The results announced today are based on management’s preliminary analysis as of this date. These figures are subject to change following the completion of our standard financial closing procedures. QHSLab anticipates releasing its detailed financial results for the first quarter in the upcoming Quarterly Report on Form 10-Q, which is scheduled to be filed with the Securities and Exchange Commission by May 14, 2024.

For more information about QHSLab and our healthcare solutions, please visit www.qhslab.com.

AboutQHSLab, Inc.

QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also improving their revenues.

Forward-LookingStatements

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

InvestorRelations Contact:

OliviaGiamanco

QHSLab,Inc.

(929)379-6503

ir@usaqcorp.com

https://twitter.com/QHSLabInc